BioSpace News Archive

Business

Biological Dynamics, an early detection disease management company, expands leadership

Biological Dynamics, an exosome isolation technology and early disease detection company, announced new executive appointments to fuel its growth.

November 10, 2022
·
3 min read
BioCapital

AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022

TIME named AstraZeneca’s EVUSHELD on their 2022 list of Best Inventions.

November 10, 2022
·
10 min read
Business

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022.

November 10, 2022
·
1 min read
Business

Enable Medicine Develops a Deep Learning Model that Establishes a New Standard for Predicting Cancer Treatment Outcomes

Enable Medicine, the platform for indexing and searching biological data, unveiled a new tool that identifies spatial-cellular signatures associated with cancer outcomes.

November 10, 2022
·
3 min read
HER2DX® Recognized by TIME as One of the Best Inventions of 2022

REVEAL GENOMICS, S.L., a biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, has announced that HER2DX® has been included as one of TIME’s “Best Inventions of 2022”.

November 10, 2022
·
4 min read
BioMidwest

Screen Usage Linked to Differences in Brain Structure in Young Children

A growing body of evidence has found that teen brains can be structurally changed by spending long spans of time playing games, watching videos and other activities on digital screens.

November 10, 2022
·
5 min read
Drug Development

CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin

CG Oncology, Inc. announced new updated data from its global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA®, for the treatment of patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

November 10, 2022
·
4 min read
BioMidwest

Nephron and Sharps Announce Manufacturing and Research Partnership

Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced a brand new partnership focused on developing and sharing best practices in innovative manufacturing, product development, customer support, and quality as Nephron prepares to launch the InjectEZ component of expansion.

November 10, 2022
·
3 min read
Policy

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. announced that the U.S. Food and Drug Administration has approved ADCETRIS® for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

November 10, 2022
·
12 min read
Business

Selvita Group reports strong business performance for Q3 YTD 2022

Selvita S.A., one of the largest contract research organizations in Europe, reported its financial results for Q3 2022. The Group continues its dynamic growth, exceeding the assumptions of the ambitious development strategy for 2022-2025 presented in March this year.

November 10, 2022
·
6 min read